EMA Withdrawn: Dasatinib Accordpharma (dasatinib) — Accord Healthcare S.L.U.

View source ↗

Summary

The EMA has withdrawn the dasatinib product Accordpharma from Accord Healthcare S.L.U. for indications including precursor cell lymphoblastic leukemia-lymphoma …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia Bcr-abl Positive
• Precursor Cell Lymphoblastic Leukemia-lymphoma

Drugs mentioned

• Dasatinib Accordpharma (dasatinib)

Snippet

Status: Withdrawn. Therapeutic area: Precursor Cell Lymphoblastic Leukemia-Lymphoma;Leukemia, Myelogenous, Chronic, BCR-ABL Positive. MAH: Accord Healthcare S.L.U.. Decision date: 22/06/2022